Ibandronic acid - Lanco Biosciences

Drug Profile

Ibandronic acid - Lanco Biosciences

Alternative Names: Ibadronate - Lanco Biosciences; LBS-101

Latest Information Update: 26 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lanco Biosciences
  • Class Antihypercalcaemics; Bisphosphonates; Calcium regulators; Osteoporosis therapies; Small molecules
  • Mechanism of Action Bone resorption factor inhibitors; Dimethylallyltranstransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Osteoporosis

Highest Development Phases

  • Preclinical Osteoporosis

Most Recent Events

  • 26 Aug 2016 Chemical structure information added
  • 12 Aug 2016 Ibandronic acid - Lanco Biosciences is available for licensing as of 12 Aug 2016. https://lancobio.com/
  • 12 Aug 2016 Preclinical trials in Osteoporosis in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top